Skip to main content
HR 4813 111th Congress House Health Abortion Business ethics Business records Competition and antitrust Disability and health-based discrimination Drug safety, medical device, and laboratory regulation Employee benefits and pensions Government trust funds Health care costs and insurance Health care coverage and access Health personnel Income tax deductions Internet and video services Internet, web applications, social media Licensing and registrations Marketing and advertising Medicaid Medicare Prescription drugs

To provide for insurance reform (including health insurance reform), amend title XVIII of the Social Security Act to reform Medicare Advantage and reduce disparities in the Medicare Program, regulate the importation of prescription drugs, and for other purposes.

Introduced: March 10, 2010 See on congress.gov
 Everywhere this bill has been 10 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 26, 2010
Referred to the Subcommittee on Immigration, Citizenship, Refugees, Border Security, and International Law.
Apr 26, 2010
Referred to the Subcommittee on Courts and Competition Policy.
Mar 22, 2010
Referred to the Subcommittee on Health, Employment, Labor, and Pensions.
Mar 10, 2010
Referred to House Education and Labor
Mar 10, 2010
Referred to House Ways and Means
Mar 10, 2010
Referred to House Oversight and Government Reform
Mar 10, 2010
Referred to House Judiciary
Mar 10, 2010
Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, Oversight and Government Reform, Ways and Means, and Education and Labor, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Mar 10, 2010
Referred to House Energy and Commerce
Mar 10, 2010
Introduced in House
 Plain-English summary Congressional Research Service

Amends the McCarran-Ferguson Act to restore application of the Clayton Act and other antitrust laws to insurers.

Prohibits premium variation except by geographic premium rating area and by family enrollment.

Requires each health benefits plan issuer that offers health insurance coverage in the individual or group market in a state to accept every employer and individual in the state that applies for such coverage.

Places restrictions on federal funding of abortion, except in cases of certain physical conditions, rape, or incest.

Limits a health benefits plan to selling health insurance coverage to U.S. citizens and lawful resident aliens.

Amends title XVIII (Medicare) and title XIX (Medicaid) of the Social Security Act to revise requirements for: (1) Medicare Advantage, with respect to the blended benchmark amount and elimination of the MA Regional Plan Stabilization Fund; (2) an increase in the physician fee schedule practice expense geographic adjustment; (3) establishment of a Medicare operated prescription drug plan option; and (4) pharmacy reimbursement.

Amends the Federal Food, Drug, and Cosmetic Act (FFDCA) to revise requirements for the importation of prescription drugs. Requires the registration of importers and exporters.

Prescribes requirements for: (1) the disposition of certain drugs denied admission into the United States; (2) alternative identification of the chain of custody of certain prescription drugs, including through the use of standardized anti-counterfeiting or track-and-trace technologies; and (3) the sale of prescription drugs through an Internet site.

Prohibits the introduction of restricted transactions with unregistered foreign pharmacies into a payment system or the completion of such transactions using a payment system.

Amends the Internal Revenue Code to disallow a deduction from income for advertising and promotional expenses for
prescription pharmaceuticals.

Requires a pharmacy benefit manager with a contract with a health benefits plan to comply with fiduciary standards established by the Secretary of Health and Human Services (HHS).

Amends SSA title XIX (Medicaid) to require any drug manufacturer with a rebate agreement concerning covered outpatient drugs to report to the HHS Secretary following a rebate period the total number of units used to calculate the monthly average manufacturer price for each covered outpatient drug.

What's happening now April 26, 2010

Referred to the Subcommittee on Immigration, Citizenship, Refugees, Border Security, and International Law.

 Committees of jurisdiction 8